Shopping Cart
Remove All
Your shopping cart is currently empty
Rovelizumab (Hu23F2G) is a humanized monoclonal antibody targeting the cell adhesion molecule CD11/CD18. It inhibits overactive leukocytes during shock and may be used in studies of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction, and stroke.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $290 | - | In Stock | |
| 5 mg | $755 | - | In Stock | |
| 10 mg | $1,200 | - | In Stock |
| Description | Rovelizumab (Hu23F2G) is a humanized monoclonal antibody targeting the cell adhesion molecule CD11/CD18. It inhibits overactive leukocytes during shock and may be used in studies of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction, and stroke. |
| In vitro | Rovelizumab binds to CD18 and exhibits activity against the CD18 integrin complex, including the CD11b-CD18 heterodimer [2]. |
| Synonyms | Hu23F2G |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | CD11/CD18 |
| Cas No. | 339086-79-2 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | IgG4 |
| Recommended Isotype Control |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.